Using the Modified Magee Equation to Identify Patients Unlikely to Benefit From the 21-Gene Recurrence Score Assay (Oncotype DX Assay). Issue 6 (25th April 2017)

• Record Type: Journal Article
• Authors: Hou, Yanjun; Tozbikian, Gary; Zynger, Debra L.; Li, Zaibo
• Is Part Of: American journal of clinical pathology. Volume 147:Issue 6(2017)
• Page Start: 541
• Page End: 548
• Publication Date: 2017-04-25
• Subjects: Breast cancer -- Estrogen receptor -- Magee equation -- Oncotype DX -- Recurrence score; Diagnosis, Laboratory -- Periodicals; Pathology -- Periodicals; 616.07
• DOI: 10.1093/ajcp/aqx008
• Languages: English
• ISSNs: 0002-9173

Abstract

Abstract : Objectives: This study aimed to compare a modified Magee equation with Oncotype DX (Genomic Health, Redwood City, CA) recurrence score (RS) and identify patients who are unlikely to benefit from Oncotype DX. Methods: Magee equation RS was calculated in 438 cases and correlated with Oncotype DX RS. Results: The Pearson correlation coefficient ( r ) for the Magee equation and Oncotype DX RS was 0.6645 ( P < .00001), and the overall agreement was 66.4%. All cases (11.6%) with a Magee equation RS greater than 30 or 11 or less had been correctly predicted to have either high Oncotype DX RS or low Oncotype DX RS, respectively. Conclusions: The modified Magee equation is able to identify up to 12% patients who are unlikely to benefit from Oncotype DX testing. Using the modified Magee equation RS on these patients would be an alternative to Oncotype DX, leading to cost savings.